Literature DB >> 8327127

Safety of anticoagulation after hemorrhagic infarction.

M S Pessin1, C J Estol, F Lafranchise, L R Caplan.   

Abstract

Cerebral hemorrhagic infarction visualized on CT, secondary to embolic stroke in an anticoagulated individual, is usually associated with clinically stable or improving neurologic signs; fear of transforming the hemorrhagic infarction into a hematoma, however, usually prompts cessation of anticoagulation until the blood has cleared on CT, despite the recognized risk of recurrent embolism during this non-anticoagulated period. We now report our experience with 12 patients with hemorrhagic infarction who remained anticoagulated. Eleven men and one woman, ages 33 to 77, developed hemorrhagic infarction while on heparin, warfarin, or both, for prevention of recurrent embolism. Patients were either continued on uninterrupted anticoagulation from stroke onset (n = 6), or anticoagulation was withheld for several days and then resumed (n = 4), or it was withheld for 5 and 14 days (n = 2) after stroke onset and then continued uninterrupted despite the CT appearance of hemorrhagic infarction. Eleven patients had a definite cardioembolic source for stroke (atrial fibrillation, seven; ventricular thrombus, two; and ventricular dyskinesia, two). One patient had carotid occlusion with local intra-arterial embolism. Hemorrhagic infarcts varied in size and were located in the middle cerebral artery territory in 11 patients and posterior cerebral artery territory in one. All patients remained clinically stable or improved on anticoagulation. Serial CTs showed fading hemorrhagic areas. When the risk of recurrent embolism is high, anticoagulation may be safely used in some patients with hemorrhagic infarction.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8327127     DOI: 10.1212/wnl.43.7.1298

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  12 in total

Review 1.  Oral anticoagulant-associated intracerebral hemorrhage.

Authors:  Alvaro Cervera; Sergio Amaro; Angel Chamorro
Journal:  J Neurol       Date:  2011-07-05       Impact factor: 4.849

Review 2.  Preventative Measures of Stroke in Patients With Atrial Fibrillation.

Authors:  Ahmed Adlan; Gregory Yh Lip
Journal:  J Atr Fibrillation       Date:  2012-04-14

Review 3.  Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association.

Authors:  Amish N Raval; Joaquin E Cigarroa; Mina K Chung; Larry J Diaz-Sandoval; Deborah Diercks; Jonathan P Piccini; Hee Soo Jung; Jeffrey B Washam; Babu G Welch; Allyson R Zazulia; Sean P Collins
Journal:  Circulation       Date:  2017-02-06       Impact factor: 29.690

Review 4.  Cardioembolic stroke: An update on etiology, diagnosis and management.

Authors:  Megan C Leary; Louis R Caplan
Journal:  Ann Indian Acad Neurol       Date:  2008-01       Impact factor: 1.714

Review 5.  Is routine computed tomography in strokes unnecessary? Costs outweigh benefits.

Authors:  S P Allison
Journal:  BMJ       Date:  1994-12-03

6.  Antithrombotic therapy in cardiac embolism.

Authors:  Alvaro Cervera; Angel Chamorro
Journal:  Curr Cardiol Rev       Date:  2010-08

Review 7.  Manipulation of coagulation factors in acute stroke.

Authors:  J F Meschia; J Biller
Journal:  Drugs       Date:  1997       Impact factor: 9.546

8.  Anticoagulant therapy with a selective thrombin inhibitor for acute cerebral infarction: usefulness of coagulation markers for evaluation of efficacy.

Authors:  Takao Urabe; Ryota Tanaka; Kazuyuki Noda; Yoshikuni Mizuno
Journal:  J Thromb Thrombolysis       Date:  2002-06       Impact factor: 2.300

9.  Stroke in inflammatory bowel disease: a report of two cases and review of the literature.

Authors:  Deepak Joshi; Tobias Dickel; Rakesh Aga; Gray Smith-Laing
Journal:  Thromb J       Date:  2008-03-21

10.  Use of antithrombotics after hemorrhagic transformation in acute ischemic stroke.

Authors:  Joon-Tae Kim; Suk-Hee Heo; Man-Seok Park; Jane Chang; Kang-Ho Choi; Ki-Hyun Cho
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.